autoimmune diseases

Autoimmune drug pipeline highlights
Autoimmune drug pipeline highlightsMore targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Four therapeutic areas to watch in 2018
Four therapeutic areas to watch in 2018Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.
New challenges, opportunities in autoimmune disease treatment
New challenges, opportunities in autoimmune disease treatmentAllegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Links shown between rosacea, other diseasesThree studies point to links between rosacea and numerous systemic comorbid diseases.
Rosacea and gastro disorders possibly relatedBecause rosacea is an inflammatory disease there is scientific rationale for a possible association between it and other inflammatory diseases. A recent study demonstrates that rosacea patients have a greater percentage of gastrointestinal disorders than do controls and should be evaluated further if they present with GI symptoms. In such cases a systematic approach to the treatment of both conditions may be warranted.
Health execs must brace for autoimmune drug changesA comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Actemra gets breakthrough therapy designation for sclerodermaThe FDA has granted breakthrough therapy designation to tocilizumab (Actemra, Genentech) for the treatment of systemic sclerosis, a rare and potentially life-threatening disease with no FDA-approved therapy.